After another record year for human challenge specialist Hvivo, chief executive Mo Khan talks us through the building blocks he’s putting in place to take the company to its longer-term target of £100m of sales by 2028.
0:30 Highlights of 2023 results, including record revenues and profitability, and Ebitda margins ahead of guidance.
1:30 Headwinds from MHRA review delays offset by client funding for new Canary Wharf facility.
2:20 What’s driving strong cash generation, and plans for regular shareholder returns.
3:40 Progress at the new Canary Wharf facility and government backing for a life science hub in the area.
6:40 How 2024 is shaping up, and how an increasingly diversified client base is improving resilience.
8:42 How the business is going to reach its longer term £200m sales target, including more human challenge models and M&A.
10:20 The value of recent attendance of the World Vaccine Congress Washington.